POLE and endometrial cancer: It has been reported that a small subset (3%–5%) of endometrial cancer patients show more than one alteration in the values for molecular classification, and endometrial cancer with a POLE mutation and abnormal p53 expression frequently showed subclonal mutant-like p53 expression [20,32].